Drugs / NT-0796
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial · 1 met primary | ||||||
| Phase 1 | NCT06129409 | Oct 2023 → Apr 2024 | cardiovascular disorder | NodThera Limited | Completed | Met primary |
| Phase 22 trials | ||||||
| Phase 2 | NCT07220629 | Oct 2025 → Aug 2026 overdue | obesity disorder | NodThera Limited | Active not recruiting | No outcome recorded |
| Phase 2 | NCT07055516 | May 2025 → May 2026 | type 2 diabetes mellitus | NodThera Limited | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-08-08 | NodThera Limited | Results NodThera Demonstrates Reversal of Neuroinflammation and Inflammation in Parkinson’s Disease with Oral NLRP3 Inhibitor rezera.com ↗
NT-0796 was shown to be safe and well tolerated, with excellent central and systemic pharmacokinetics and high target engagement in both healthy volunteers and Parkinson’s disease patients. |
| 2026-08-08 | NodThera Limited | Results NodThera Announces the Publication and Presentation of Cardiometabolic Clinical Data Supporting the Potential of Ruvonoflast to Treat Inflammation at the Source rezera.com ↗ |
| 2026-08-05 | NodThera Limited | Results NodThera’s Oral NLRP3 Inhibitor NT-0796 Enhances and Sustains Weight Loss in Combination with GLP-1 rezera.com ↗
These data, published in the research journal Obesity, show that combined dosing of NodThera’s NT-0796 with semaglutide (Wegovy®) drove greater weight loss than either monotherapy in an animal model of obesity. |
All press releases naming this drug 4 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NT-0796 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07055516 ↗ |
| Modality | Small molecule | — CHEMBL5409389 ↗ |
| Route | Oral | “Study drug will be administered orally.” NCT07055516 ↗ |